The Chinese government is to step up scrutiny of the cost effectiveness of its medical treatments, under a new technical co-operation agreement signed with the UK’s drug advisory body.
The China National Health Development Research Centre will start work with the National Institute for Health and Clinical Excellence (Nice) on a range of projects including analysing the costs and benefits of kidney screening and childhood leukaemia.
The studies could pave the way for a wide-ranging restructuring of China’s fast-developing healthcare system.
您已阅读36%（543字），剩余64%（969字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。